Answers are grounded in this paper and cite their sources.
Real-world comparative study reveals distinct toxicity profiles of carmustine-substituted regimens in lymphoma after ASCT, suggesting personalized approaches.
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) remains a key consolidation strategy for patients with relapsed/refractory (R/R) lymphoma. The BEAM regimen (carmustine, etoposide, cytarabine, melphalan) is the standard conditioning therapy, but clinical carmustine supply shortages have necessitated the search for alternatives. This study compared the toxicity and transplant outcomes of four carmustine-substituted conditioning regimens. We retrospectively analyzed 80 lymphoma patients who underwent ASCT between January 2018 and December 2023. Patients received one of four regimens: BeEAM (bendamustine, etoposide, cytarabine, melphalan; n = 16), CBV (cyclophosphamide, oral semustine, etoposide; n = 12), CEAC (oral semustine, etoposide, cytarabine, cyclophosphamide; n = 16), or SEAM (oral semustine, etoposide, cytarabine, melphalan; n = 36). The primary endpoint was severe toxicity. Secondary endpoints included progression-free survival (PFS), overall survival (OS), complete response rate (CRR) and non-relapse mortality. The SEAM regimen was associated with a significantly higher rate of BNP elevation (61.1%, p = 0.040). All patients in the BeEAM group developed febrile neutropenia (p = 0.004), and this regimen also led to more platelet transfusions (median 6.5 units, p = 0.001) and longer hospital stays (median 28.5 days, p = 0.012). The CBV group had the highest rate of cardiovascular adverse events (25.0%, p = 0.081), while the CEAC group showed the highest incidence of hypoproteinemia (100.0%, p = 0.006) and a notably high rate of intestinal infection (81.3%, p = 0.069). No significant intergroup differences were observed in PFS, OS, day + 100 CRR, or non-relapse mortality. Multivariate Cox analysis identified pre-transplant partial remission as an independent adverse prognostic factor for PFS (HR: 4.864; 95% CI: 1.094-21.634, p = 0.038). Although the four carmustine-substituted conditioning regimens demonstrated similar efficacy outcomes for ASCT in lymphoma patients, their distinct toxicity profiles highlight the need for personalized regimen selection, particularly in the context of carmustine shortages.
No takes yet. Share an insight, caveat, or question.
Pang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: